ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1917

A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial

William Leach1, Marianna Olave1, Caleigh Doherty2, Rachel Gillcrist1, Daniel White3, Keith Robinson1, Alexis Ogdie4, Tuhina Neogi5, Carla Scanzello6 and Joshua Baker6, 1Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3University of Delaware, Newark, DE, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Boston University School of Medicine, Boston, MA, 6University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: exercise, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: In this pilot and feasibility study, we evaluated whether a behaviorally-designed intervention utilizing gamification and social support could improve both physical activity and reduce symptoms in veterans with osteoarthritis of the knee (KOA). We hypothesized that the weekly average of daily steps over 32 weeks of follow-up would be greater in participants randomized into the intervention arm compared to the control arm and that symptoms of KOA would be reduced over time.

Methods: Veterans with a diagnosis of KOA, 40-80 years old, and who did not use assistive devices for ambulation were enrolled. Participants received a FitbitTM and completed an initial 2-4 week observation period. A web-based platform administered surveys on a biweekly basis and tracked physical activity through linkage to the FitbitTM application. All participants selected a daily step goal that was either 33%, 40%, or 50% above their baseline. The intervention arm received points and advanced through levels based on performance. They also selected a social support partner that received updates on their progress to help motivate participants to meet their step goals. Controls received only daily texts with their step counts from the prior day. Participants were also randomized to receive corticosteroid injections vs. lidocaine only in a factorial design (not shown here). The primary outcome was the change in average daily steps over 32 weeks. Step counts were averaged over 2-week periods and analyzed over all time-points using mixed effects regression and adjusting for baseline (days with < 1000 steps were considered missing). Secondary outcomes included the total Knee Osteoarthritis Outcome Score (KOOS) assessed over all time points. We determined differences in slope of change in KOOS between the intervention and control arms.

Results: Of the 36 consented participants, 33 were randomized and 31 were included in the final analysis. Two patients were withdrawn due to lack of participation. Most participants were male (90.3%) and Black (70.96%). The mean (SD) age and BMI of the study population were 60 (13) years old and 33.7 (5.9) kg/m2, respectively. Diabetes (42%), hypertension (42%), and sleep apnea (45%), were the most common comorbidities and were comparably distributed between the trial arms. Over all observations, participants that received the intervention walked a total of 1119 (95% CI: -562, 2799) more steps per day compared with the control arm (P=0.19) (Figure 1). The effect was greatest in the first 6-months (180 days) [1491 (-272, 3254) p=0.10]. Greater improvement in total KOOS and several sub-scales was observed in participants that received the intervention (Table 1).

Conclusion: This remote behaviorally-designed intervention might help patients achieve improvements in both steps per day and symptoms over 32 weeks. A larger, multi-site study is underway and will provide greater precision with regard to the degree to which this intervention is effective in promoting exercise and reducing symptoms of KOA.

Supporting image 2

Table 1: Slope of change (per 14 days) extrapolated from mixed effects regression models stratified by the incentive and control arms. *p<0.05 comparing the slope of change to 0 (i.e. no change).


Disclosures: W. Leach, None; M. Olave, None; C. Doherty, None; R. Gillcrist, None; D. White, None; K. Robinson, None; A. Ogdie, AbbVie, Amgen, Novartis, Pfizer Inc, Bristol-Myers Squibb, Celgene, Janssen, CorEvitas, Gilead Sciences, Eli Lilly, GlaxoSmithKline, Happify Health, UCB; T. Neogi, Novartis, Pfizer/Lilly, Regeneron; C. Scanzello, None; J. Baker, Bristol-Myers Squibb(BMS), RediTrex, Pfizer.

To cite this abstract in AMA style:

Leach W, Olave M, Doherty C, Gillcrist R, White D, Robinson K, Ogdie A, Neogi T, Scanzello C, Baker J. A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-remote-behaviorally-designed-intervention-to-promote-physical-activity-in-patients-with-knee-osteoarthritis-results-of-a-pilot-randomized-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-remote-behaviorally-designed-intervention-to-promote-physical-activity-in-patients-with-knee-osteoarthritis-results-of-a-pilot-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology